Author: Khattar, Sunil K.; Nayak, Baibaswata; Kim, Shin-Hee; Xiao, Sa; Samal, Sweety; Paldurai, Anandan; Buchholz, Ursula J.; Collins, Peter L.; Samal, Siba K.
Title: Evaluation of the Replication, Pathogenicity, and Immunogenicity of Avian Paramyxovirus (APMV) Serotypes 2, 3, 4, 5, 7, and 9 in Rhesus Macaques Document date: 2013_10_10
ID: 0littefv_34
Snippet: Therefore, the goal of this study was to evaluate the replication and pathogenicity of a number of non-NDV APMV serotypes in non-human primates. Rhesus macaques were evaluated for permissiveness to infection, clinical disease, magnitude of replication, shedding and induction of antibodies. Rhesus macaques have been used commonly as a non-human primate model to study replication and pathogenicity of various viruses, to screen attenuation phenotype.....
Document: Therefore, the goal of this study was to evaluate the replication and pathogenicity of a number of non-NDV APMV serotypes in non-human primates. Rhesus macaques were evaluated for permissiveness to infection, clinical disease, magnitude of replication, shedding and induction of antibodies. Rhesus macaques have been used commonly as a non-human primate model to study replication and pathogenicity of various viruses, to screen attenuation phenotypes of live virus vaccines, and to evaluate immune responses of virus vaccine candidates. The safety, immunogenicity, and protective efficacy of NDV has also been demonstrated in this model [29] [30] [31] [32] [33] 51] .
Search related documents:
Co phrase search for related documents- attenuation phenotype and immune response: 1
- attenuation phenotype and live virus vaccine: 1
- attenuation phenotype and pathogenicity replication: 1
- attenuation phenotype and virus vaccine: 1
- clinical disease and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical disease and infection permissiveness: 1
- clinical disease and live virus vaccine: 1, 2, 3, 4, 5
- clinical disease and model demonstrate: 1, 2, 3, 4, 5
- clinical disease and non human primate: 1, 2, 3, 4
- clinical disease and pathogenicity replication: 1, 2, 3
- clinical disease and primate model: 1, 2, 3, 4, 5, 6, 7
- clinical disease and protective efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- clinical disease and protective efficacy immunogenicity: 1, 2, 3, 4, 5, 6, 7
- clinical disease and Rhesus macaque: 1, 2, 3, 4, 5, 6, 7, 8
- clinical disease and study goal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- clinical disease and virus vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- clinical disease and virus vaccine candidate: 1, 2
- immune response and induction shedding: 1
- immune response and infection permissiveness: 1, 2
Co phrase search for related documents, hyperlinks ordered by date